Heron Therapeutics market cap is $1.3 b, and annual revenue was $88.64 m in FY 2020

Heron Therapeutics Gross profit (FY, 2020)52.4 M

Heron Therapeutics Gross profit margin (FY, 2020), %59.2%

Heron Therapeutics Net income (FY, 2020)-227.3 M

Heron Therapeutics EBIT (FY, 2020)-228.2 M

Heron Therapeutics Cash, 31-Dec-2020105.1 M

Heron Therapeutics EV1.2 B

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 646.0k | 1.3m | 30.8m | 77.5m | 146.0m | 88.6m | ||||

## Cost of goods sold | 35.0k | 4.6m | 27.5m | 61.6m | 36.2m | |||||

## Gross profit | 1.2m | 26.2m | 50.0m | 84.3m | 52.4m | |||||

| 97% | 85% | 64% | 58% | 59% | |||||

## Sales and marketing expense | 47.7m | 56.6m | 64.6m | 89.8m | 63.9m | |||||

## R&D expense | 8.2m | 15.0m | 32.8m | 54.8m | 61.2m | 103.1m | 138.6m | 140.0m | 167.4m | 174.5m |

## General and administrative expense | 3.5m | 8.8m | 21.7m | 19.7m | 35.7m | 21.4m | 25.6m | 29.3m | 37.9m | 42.2m |

## Operating expense total | 11.7m | 23.8m | 54.5m | 74.6m | 96.9m | 172.2m | 220.7m | 233.9m | 295.0m | 280.6m |

## EBIT | (11.1m) | (23.8m) | (54.5m) | (74.6m) | (96.9m) | (170.9m) | (194.6m) | (183.9m) | (210.7m) | (228.2m) |

| (1712%) | (13363%) | (632%) | (237%) | (144%) | (257%) | ||||

## Interest expense | 373.0k | 599.0k | 826.0k | 1.8m | 2.2m | 2.9m | 5.1m | 5.9m | ||

## Interest income | 1.0m | 6.0m | 7.3m | 3.6m | ||||||

## Pre tax profit | (11.4m) | |||||||||

## Income tax expense | ||||||||||

## Net Income | (11.8m) | (23.3m) | (55.3m) | (76.4m) | (97.6m) | (173.1m) | (197.5m) | (178.8m) | (204.7m) | (227.3m) |

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (11.8m) | (23.3m) | (55.3m) | (76.4m) | (97.6m) | (173.1m) | (197.5m) | (178.8m) | (204.7m) | (227.3m) |

## Depreciation and Amortization | 179.0k | 197.0k | 333.0k | 578.0k | 734.0k | 1.1m | 1.5m | 1.5m | 2.0m | |

## Accounts Receivable | (110.0k) | (2.0m) | (39.9m) | (22.8m) | 24.8m | (2.0m) | ||||

## Inventories | (5.3m) | (4.8m) | (29.1m) | 14.1m | (16.9m) | |||||

## Accounts Payable | 467.0k | 984.0k | (426.0k) | 1.3m | 751.0k | 3.5m | 12.0m | (1.9m) | (14.1m) | (2.2m) |

## Cash From Operating Activities | (7.7m) | (17.0m) | (40.8m) | (60.3m) | (78.5m) | (134.1m) | (170.3m) | (191.8m) | (124.6m) | (184.8m) |

## Purchases of PP&E | (513.0k) | (972.0k) | (1.7m) | (1.4m) | (1.1m) | (3.1m) | (2.6m) | (9.2m) | (7.2m) | (6.8m) |

## Cash From Investing Activities | (513.0k) | (972.0k) | (1.7m) | (1.4m) | (57.0m) | 14.9m | 7.7m | (278.5m) | (21.8m) | 209.0m |

## Long-term Borrowings | (25.0m) | (25.0m) | ||||||||

## Cash From Financing Activities | 24.1m | 53.5m | 61.2m | 62.1m | 138.0m | 57.5m | 293.7m | 357.6m | 186.4m | 9.1m |

## Net Change in Cash | 15.9m | 35.5m | 18.8m | 388.0k | 2.5m | (61.8m) | 131.2m | (112.7m) | 40.1m | 33.2m |

## Interest Paid | 2.0k | 1.6m | 2.8m | 1.2m |

USD | Q2, 2011 |
---|---|

## Financial Leverage | 1.2 x |